Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

EpCAM-based assays for epithelial tumor cell detection in cerebrospinal fluid.

van Bussel MTJ, Pluim D, Bol M, Beijnen JH, Schellens JHM, Brandsma D.

J Neurooncol. 2018 Mar;137(1):1-10. doi: 10.1007/s11060-017-2691-6. Epub 2017 Nov 30. Review.

PMID:
29192390
2.

Improved pharmacodynamic (PD) assessment of low dose PARP inhibitor PD activity for radiotherapy and chemotherapy combination trials.

de Haan R, Pluim D, van Triest B, van den Heuvel M, Peulen H, van Berlo D, George J, Verheij M, Schellens JHM, Vens C.

Radiother Oncol. 2018 Mar;126(3):443-449. doi: 10.1016/j.radonc.2017.10.017. Epub 2017 Nov 14.

3.

Dihydrofolate Reductase/Thymidylate Synthase Fine-Tunes the Folate Status and Controls Redox Homeostasis in Plants.

Gorelova V, De Lepeleire J, Van Daele J, Pluim D, Meï C, Cuypers A, Leroux O, Rébeillé F, Schellens JHM, Blancquaert D, Stove CP, Van Der Straeten D.

Plant Cell. 2017 Nov;29(11):2831-2853. doi: 10.1105/tpc.17.00433. Epub 2017 Sep 22.

PMID:
28939595
4.

Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months.

Leijen S, van Geel RM, Sonke GS, de Jong D, Rosenberg EH, Marchetti S, Pluim D, van Werkhoven E, Rose S, Lee MA, Freshwater T, Beijnen JH, Schellens JH.

J Clin Oncol. 2016 Dec 20;34(36):4354-4361. Epub 2016 Oct 28.

PMID:
27998224
5.

Pronounced between-subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteers.

Jacobs BA, Deenen MJ, Pluim D, van Hasselt JG, Krähenbühl MD, van Geel RM, de Vries N, Rosing H, Meulendijks D, Burylo AM, Cats A, Beijnen JH, Huitema AD, Schellens JH.

Br J Clin Pharmacol. 2016 Sep;82(3):706-16. doi: 10.1111/bcp.13007. Epub 2016 Jun 3.

6.

A phase 0 clinical trial of novel candidate extended-release formulations of capecitabine.

Jacobs BA, Meulenaar J, Rosing H, Pluim D, Tibben MM, de Vries N, Nuijen B, Huitema AD, Beijnen JH, Schellens JH, Marchetti S.

Cancer Chemother Pharmacol. 2016 Jun;77(6):1201-7. doi: 10.1007/s00280-016-3035-5. Epub 2016 Apr 21.

PMID:
27103124
7.

Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study.

Meulendijks D, de Groot JW, Los M, Boers JE, Beerepoot LV, Polee MB, Beeker A, Portielje JE, Goey SH, de Jong RS, Vanhoutvin SA, Kuiper M, Sikorska K, Pluim D, Beijnen JH, Schellens JH, Grootscholten C, Tesselaar ME, Cats A.

Cancer. 2016 May 1;122(9):1434-43. doi: 10.1002/cncr.29864. Epub 2016 Mar 11.

8.

EpCAM-based flow cytometry in cerebrospinal fluid greatly improves diagnostic accuracy of leptomeningeal metastases from epithelial tumors.

Milojkovic Kerklaan B, Pluim D, Bol M, Hofland I, Westerga J, van Tinteren H, Beijnen JH, Boogerd W, Schellens JH, Brandsma D.

Neuro Oncol. 2016 Jun;18(6):855-62. doi: 10.1093/neuonc/nov273. Epub 2015 Nov 12.

9.

Increased risk of severe fluoropyrimidine-associated toxicity in patients carrying a G to C substitution in the first 28-bp tandem repeat of the thymidylate synthase 2R allele.

Meulendijks D, Jacobs BA, Aliev A, Pluim D, van Werkhoven E, Deenen MJ, Beijnen JH, Cats A, Schellens JH.

Int J Cancer. 2016 Jan 1;138(1):245-53. doi: 10.1002/ijc.29694. Epub 2015 Oct 1.

10.

Improved pharmacodynamic assay for dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells.

Pluim D, Jacobs BA, Deenen MJ, Ruijter AE, van Geel RM, Burylo AM, Meulendijks D, Beijnen JH, Schellens JH.

Bioanalysis. 2015;7(5):519-29. doi: 10.4155/bio.14.304.

PMID:
25826134
11.

Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy.

Leijen S, Burgers SA, Baas P, Pluim D, Tibben M, van Werkhoven E, Alessio E, Sava G, Beijnen JH, Schellens JH.

Invest New Drugs. 2015 Feb;33(1):201-14. doi: 10.1007/s10637-014-0179-1. Epub 2014 Oct 25.

PMID:
25344453
12.

"Effect of the drug transporters ABCB1, ABCC2, and ABCG2 on the disposition and brain accumulation of the taxane analog BMS-275,183".

Marchetti S, Pluim D, Beijnen JH, Mazzanti R, van Tellingen O, Schellens JH.

Invest New Drugs. 2014 Dec;32(6):1083-95. doi: 10.1007/s10637-014-0143-0. Epub 2014 Jul 31.

PMID:
25078948
13.

Abcc4 together with abcb1 and abcg2 form a robust cooperative drug efflux system that restricts the brain entry of camptothecin analogues.

Lin F, Marchetti S, Pluim D, Iusuf D, Mazzanti R, Schellens JH, Beijnen JH, van Tellingen O.

Clin Cancer Res. 2013 Apr 15;19(8):2084-95. doi: 10.1158/1078-0432.CCR-12-3105. Epub 2013 Mar 5.

14.

Correction of peripheral blood mononuclear cell cytosolic protein for hemoglobin contamination.

Pluim D, Jacobs BA, Krähenbühl MD, Ruijter AE, Beijnen JH, Schellens JH.

Anal Bioanal Chem. 2013 Mar;405(7):2391-5. doi: 10.1007/s00216-012-6614-2. Epub 2013 Jan 15.

PMID:
23318760
15.

Effect of the drug transporters ABCG2, Abcg2, ABCB1 and ABCC2 on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA.

Marchetti S, Pluim D, van Eijndhoven M, van Tellingen O, Mazzanti R, Beijnen JH, Schellens JH.

Invest New Drugs. 2013 Oct;31(5):1125-35. doi: 10.1007/s10637-013-9923-1. Epub 2013 Jan 13. Erratum in: Invest New Drugs. 2013 Jun;31(3):800.

PMID:
23315030
16.

Pharmacodynamic assay of thymidylate synthase activity in peripheral blood mononuclear cells.

Pluim D, Schilders KA, Jacobs BA, Vaartjes D, Beijnen JH, Schellens JH.

Anal Bioanal Chem. 2013 Mar;405(8):2495-503. doi: 10.1007/s00216-012-6676-1. Epub 2013 Jan 12.

PMID:
23314484
17.

Validation of a multiparameter flow cytometry method for the determination of phosphorylated extracellular-signal-regulated kinase and DNA in circulating tumor cells.

Pluim D, Devriese LA, Beijnen JH, Schellens JH.

Cytometry A. 2012 Aug;81(8):664-71. doi: 10.1002/cyto.a.22049. Epub 2012 Apr 12.

18.

Simultaneous determination of AZD1152 (prodrug) and AZD1152-hydroxyquinazoline pyrazol anilide by reversed phase liquid chromatography.

Pluim D, Beijnen JH, Schellens JH, van Tellingen O.

J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Nov 1;877(29):3549-55. doi: 10.1016/j.jchromb.2009.08.035. Epub 2009 Aug 28.

PMID:
19744901
19.

Phase I pharmacokinetic and pharmacodynamic study of Carboplatin and topotecan administered intravenously every 28 days to patients with malignant solid tumors.

Boss DS, Siegel-Lakhai WS, van Egmond-Schoemaker NE, Pluim D, Rosing H, Ten Bokkel Huinink WW, Beijnen JH, Schellens JH.

Clin Cancer Res. 2009 Jul 1;15(13):4475-83. doi: 10.1158/1078-0432.CCR-08-3144. Epub 2009 Jun 16.

20.

New insights into the pharmacology and cytotoxicity of gemcitabine and 2',2'-difluorodeoxyuridine.

Veltkamp SA, Pluim D, van Eijndhoven MA, Bolijn MJ, Ong FH, Govindarajan R, Unadkat JD, Beijnen JH, Schellens JH.

Mol Cancer Ther. 2008 Aug;7(8):2415-25. doi: 10.1158/1535-7163.MCT-08-0137.

21.

Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study.

Veltkamp SA, Jansen RS, Callies S, Pluim D, Visseren-Grul CM, Rosing H, Kloeker-Rhoades S, Andre VA, Beijnen JH, Slapak CA, Schellens JH.

Clin Cancer Res. 2008 Jun 1;14(11):3477-86. doi: 10.1158/1078-0432.CCR-07-4521.

22.

Extensive metabolism and hepatic accumulation of gemcitabine after multiple oral and intravenous administration in mice.

Veltkamp SA, Pluim D, van Tellingen O, Beijnen JH, Schellens JH.

Drug Metab Dispos. 2008 Aug;36(8):1606-15. doi: 10.1124/dmd.108.021048. Epub 2008 May 19.

23.

Inductively coupled plasma mass spectrometric analysis of the total amount of platinum in DNA extracts from peripheral blood mononuclear cells and tissue from patients treated with cisplatin.

Brouwers EE, Tibben MM, Pluim D, Rosing H, Boot H, Cats A, Schellens JH, Beijnen JH.

Anal Bioanal Chem. 2008 May;391(2):577-85. doi: 10.1007/s00216-008-2034-8. Epub 2008 Apr 3.

PMID:
18385987
24.

In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2.

Marchetti S, Oostendorp RL, Pluim D, van Eijndhoven M, van Tellingen O, Schinkel AH, Versace R, Beijnen JH, Mazzanti R, Schellens JH.

Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3307-13.

25.

Cisplatin-DNA adduct formation in patients treated with cisplatin-based chemoradiation: lack of correlation between normal tissues and primary tumor.

Hoebers FJ, Pluim D, Hart AA, Verheij M, Balm AJ, Fons G, Rasch CR, Schellens JH, Stalpers LJ, Bartelink H, Begg AC.

Cancer Chemother Pharmacol. 2008 May;61(6):1075-81. Epub 2007 Jul 18.

26.

The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models.

Breedveld P, Pluim D, Cipriani G, Dahlhaus F, van Eijndhoven MA, de Wolf CJ, Kuil A, Beijnen JH, Scheffer GL, Jansen G, Borst P, Schellens JH.

Mol Pharmacol. 2007 Jan;71(1):240-9. Epub 2006 Oct 10.

27.

Adduct-specific monoclonal antibodies for the measurement of cisplatin-induced DNA lesions in individual cell nuclei.

Liedert B, Pluim D, Schellens J, Thomale J.

Nucleic Acids Res. 2006 Mar 29;34(6):e47.

28.
29.

Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumours.

Siegel-Lakhai WS, Crul M, Zhang S, Sparidans RW, Pluim D, Howes A, Solanki B, Beijnen JH, Schellens JH.

Br J Cancer. 2005 Nov 28;93(11):1222-9.

30.

Phase I clinical and pharmacologic study of a 2-weekly administration of cisplatin and gemcitabine in patients with advanced non-small cell lung cancer.

Rademaker-Lakhai JM, Crul M, Pluim D, Sparidans RW, Baas P, Beijnen JH, van Zandwijk N, Schellens JH.

Anticancer Drugs. 2005 Oct;16(9):1029-36.

PMID:
16162981
31.

Human metabolism of [(14)C]indisulam following i.v. infusion in cancer patients.

Beumer JH, Hillebrand MJ, Pluim D, Rosing H, Foley K, Yule SM, Schellens JH, Beijnen JH.

Invest New Drugs. 2005 Aug;23(4):317-30.

PMID:
16012791
33.

Platinated DNA adducts enhance poisoning of DNA topoisomerase I by camptothecin.

van Waardenburg RC, de Jong LA, van Eijndhoven MA, Verseyden C, Pluim D, Jansen LE, Bjornsti MA, Schellens JH.

J Biol Chem. 2004 Dec 24;279(52):54502-9. Epub 2004 Oct 6.

34.

Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions.

Breedveld P, Zelcer N, Pluim D, Sönmezer O, Tibben MM, Beijnen JH, Schinkel AH, van Tellingen O, Borst P, Schellens JH.

Cancer Res. 2004 Aug 15;64(16):5804-11.

35.

A Phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent.

Rademaker-Lakhai JM, van den Bongard D, Pluim D, Beijnen JH, Schellens JH.

Clin Cancer Res. 2004 Jun 1;10(11):3717-27.

36.

A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors.

Rademaker-Lakhai JM, Terret C, Howell SB, Baud CM, De Boer RF, Pluim D, Beijnen JH, Schellens JH, Droz JP.

Clin Cancer Res. 2004 May 15;10(10):3386-95.

37.

Cytotoxicity of the organic ruthenium anticancer drug Nami-A is correlated with DNA binding in four different human tumor cell lines.

Pluim D, van Waardenburg RC, Beijnen JH, Schellens JH.

Cancer Chemother Pharmacol. 2004 Jul;54(1):71-8. Epub 2004 Mar 19.

PMID:
15034754
38.

Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma.

Zamboni WC, Gervais AC, Egorin MJ, Schellens JH, Zuhowski EG, Pluim D, Joseph E, Hamburger DR, Working PK, Colbern G, Tonda ME, Potter DM, Eiseman JL.

Cancer Chemother Pharmacol. 2004 Apr;53(4):329-36. Epub 2003 Dec 12.

PMID:
14673619
39.

Endovascular lung perfusion using high-dose cisplatin: uptake and DNA adduct formation in an animal model.

Brown DB, Ma MK, Battafarano RJ, Naidu S, Pluim D, Zamboni WC, McLeod HL.

Oncol Rep. 2004 Jan;11(1):237-43.

PMID:
14654932
40.

Randomized phase I clinical and pharmacologic study of weekly versus twice-weekly dose-intensive cisplatin and gemcitabine in patients with advanced non-small cell lung cancer.

Crul M, Schoemaker NE, Pluim D, Maliepaard M, Underberg RW, Schot M, Sparidans RW, Baas P, Beijnen JH, Van Zandwijk N, Schellens JH.

Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3526-33.

41.

In vitro pharmacokinetic study of the novel anticancer agent E7070: red blood cell and plasma protein binding in human blood.

Bongard HJ, Pluim D, Waardenburg RC, Ravic M, Beijnen JH, Schellens JH.

Anticancer Drugs. 2003 Jul;14(6):405-10.

PMID:
12853880
42.

DNA repair mechanisms involved in gemcitabine cytotoxicity and in the interaction between gemcitabine and cisplatin.

Crul M, van Waardenburg RC, Bocxe S, van Eijndhoven MA, Pluim D, Beijnen JH, Schellens JH.

Biochem Pharmacol. 2003 Jan 15;65(2):275-82.

PMID:
12504803
43.

An excretion balance and pharmacokinetic study of the novel anticancer agent E7070 in cancer patients.

van sen Bongard HJ, Pluim D, Rosing H, Nan-Offeringa L, Schot M, Ravic M, Schellens JH, Beijnen JH.

Anticancer Drugs. 2002 Sep;13(8):807-14.

PMID:
12394264
44.

Inter- and intratumoral disposition of platinum in solid tumors after administration of cisplatin.

Zamboni WC, Gervais AC, Egorin MJ, Schellens JH, Hamburger DR, Delauter BJ, Grim A, Zuhowski EG, Joseph E, Pluim D, Potter DM, Eiseman JL.

Clin Cancer Res. 2002 Sep;8(9):2992-9.

45.

Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin.

Meerum Terwogt JM, Groenewegen G, Pluim D, Maliepaard M, Tibben MM, Huisman A, ten Bokkel Huinink WW, Schot M, Welbank H, Voest EE, Beijnen JH, Schellens JM.

Cancer Chemother Pharmacol. 2002 Mar;49(3):201-10. Epub 2002 Jan 22.

PMID:
11935212
46.

Topoisomerase I levels in white blood cells of patients with ovarian cancer treated with paclitaxel-cisplatin-topotecan in a phase I study.

Schoemaker NE, Herben VM, de Jong LA, van Waardenburg RC, Pluim D, ten Bokkel Huinink WW, Beijnen JH, Schellens JH.

Anticancer Drugs. 2002 Jan;13(1):87-91.

PMID:
11914645
47.

Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918.

Maliepaard M, van Gastelen MA, Tohgo A, Hausheer FH, van Waardenburg RC, de Jong LA, Pluim D, Beijnen JH, Schellens JH.

Clin Cancer Res. 2001 Apr;7(4):935-41.

48.

32P-postlabeling assay for the quantification of the major platinum-DNA adducts.

Pluim D, Maliepaard M, van Waardenburg RC, Beijnen JH, Schellens JH.

Anal Biochem. 1999 Nov 1;275(1):30-8.

PMID:
10542106
49.

Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line.

Maliepaard M, van Gastelen MA, de Jong LA, Pluim D, van Waardenburg RC, Ruevekamp-Helmers MC, Floot BG, Schellens JH.

Cancer Res. 1999 Sep 15;59(18):4559-63.

50.

In vitro antagonistic cytotoxic interactions between platinum drugs and taxanes on bone marrow progenitor cell CFU-GM.

de Graaff M, Maliepaard M, Pluim D, Floot BJ, Slaper-Cortenbach IC, Schellens JH.

Anticancer Drugs. 1999 Feb;10(2):213-8.

PMID:
10211552

Supplemental Content

Support Center